Abstract
Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
Volume: 20 Issue: 7
Author(s): Pallavi Singh Chauhan, Meerambika Mishra, Bhupendra Koul, Mayank Sharma and Dhananjay Yadav*
Affiliation:
- Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541,South Korea
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Abstract: Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Export Options
About this article
Cite this article as:
Chauhan Singh Pallavi , Mishra Meerambika , Koul Bhupendra , Sharma Mayank and Yadav Dhananjay *, Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance, CNS & Neurological Disorders - Drug Targets 2021; 20 (7) . https://dx.doi.org/10.2174/1871527320666210319111852
DOI https://dx.doi.org/10.2174/1871527320666210319111852 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Antibacterial Agents: An Emergent Need to Win the Battle Against Infections
Mini-Reviews in Medicinal Chemistry Clinical Pharmacology of Current and Future Drugs for the Acute Treatment of Migraine: A Review and An Update
Current Clinical Pharmacology Clinical Presentation, Treatment Outcome and Survival Among the HIV Infected Children with Culture Confirmed Tuberculosis
Current HIV Research Evaluation of Small Molecule Tuberculostats for Targeting Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry The Efficacy of Viral Capsid Inhibitors in Human Enterovirus Infection and Associated Diseases
Current Medicinal Chemistry Current Status of Carbapenem Antibiotics
Current Topics in Medicinal Chemistry Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Developing Country Applications of Molecular Farming: Case Studies in South Africa and Argentina
Current Pharmaceutical Design Reporting Rates of Yellow Fever Vaccine 17D or 17DD-Associated Serious Adverse Events in Pharmacovigilance Data Bases: Systematic Review
Current Drug Safety Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Status Epilepticus: An Overview
Current Drug Metabolism Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry In-silico Subtractive Proteomic Analysis Approach for Therapeutic Targets in MDR Salmonella enterica subsp. enterica serovar Typhi str. CT18
Current Topics in Medicinal Chemistry HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Porphyromonas gingivalis Mediated Periodontal Disease and Atherosclerosis:Disparate Diseases with Commonalities in Pathogenesis Through TLRs
Current Pharmaceutical Design Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Mechanisms of Brain Signaling During Sepsis
Current Neuropharmacology Case Series and Mini-Review on Elizabethkingia meningoseptica, A high Alert Organism Causing Meningitis in Premature Neonates from A Tertiary Care Hospital of Western Rajasthan
Infectious Disorders - Drug Targets